Aquestive Therapeutics
AQST
54 hedge funds and large institutions have $31.5M invested in Aquestive Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 5 closing their positions.
894% more call options, than puts
Call options by funds: $179K | Put options by funds: $18K
800% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 2
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
85% more capital invested
Capital invested by funds: $17M → $31.5M (+$14.5M)
54% more funds holding
Funds holding: 35 → 54 (+19)
6.54% more ownership
Funds ownership: 27.58% → 34.11% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.09M |
| 2 |
Renaissance Technologies
New York
|
+$1.29M |
| 3 |
Walleye Capital
New York
|
+$731K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$493K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$451K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$98.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.7K |
| 3 |
Jane Street
New York
|
-$26.7K |
| 4 |
VF
Virtu Financial
New York
|
-$15K |
| 5 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$9.04K |
AQST Hedge Fund Activity: Q2 2023 in Review
54 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2023, worth a combined $31.5M — up 85% from $17M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AQST positions and 5 closed out — a net gain of 19 holders — while 18 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.09M. The largest seller was Kestra Advisory Services, exiting entirely with an estimated $98.4K sold.
- 54 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2023, up from 35 in Q1 2023.
- Funds reported $31.5M of Aquestive Therapeutics stock for Q2 2023, up 85% quarter-over-quarter.
- 24 funds opened new Aquestive Therapeutics positions in Q2 2023 and 5 closed out, a net change of +19 holders.
- The largest Aquestive Therapeutics buyer in Q2 2023 was Armistice Capital, an estimated $2.09M added.
- The largest Aquestive Therapeutics seller in Q2 2023 was Kestra Advisory Services, an estimated $98.4K sold.
Based on aggregated 13F filings for Q2 2023.